Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PyVST for Progressive Multifocal Leukoencephalopathy
NCT02694783Phase 1Completed
- Sponsor
- National Institute of Neurological Disorders and Stroke
- Start
- Mar 2016
- Primary completion
- Dec 2019
- Modality
- Native Immune Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PyVST in progressive multifocal leukoencephalopathy (PML), sponsored by National Institute of Neurological Disorders and Stroke. Primary endpoint: Treatment Limiting Toxicity. Started Mar 2016; status: completed.
02
Drugs
PyVST
03
Conditions
progressive multifocal leukoencephalopathy (PML)
Beyond the preview
Go deeper on NCT02694783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02694783.